Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

What is claimed is

1. (Previously Presented) A compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, -$(CH_2)_qOR^{11}$, -$NR^{11}C(O)R^{12}$, -$NR^{11}SO_2R^{12}$,
-$SO_2NR^{11}R^{12}$, -$NR^{11}R^{12}$, -$OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$,
and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents –NHR^{14} and R^7 and –NHR^{14} together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, –OR^{11} or –$NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, haloC_{1-4} alkyl, -OR^{11}, –NR^{11} R^{12}, -$OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $-OC(O)NR^{11}R^{12}$, R^{11} and R^{12} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl,
hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4.

2. (Currently Amended) A compound according to Claim 1, wherein R^8 is selected from the group consisting of halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$, ~~or~~ $OC(O)NR^{11}R^{12}$, and
$-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring.

3. (Previously Presented) A compound according to claim 1 wherein R^1 represents $-SO_2R^6$.

4. (Previous Presented) A compound according to claim 1 wherein R^6 represents a C_{3-7} cycloalkyl group.

5. (Previously Presented) A compound according to claim 1 wherein R^2 and R^3 each represent hydrogen.

6. (Previously Presented) A compound according to claim 1 wherein R^4 and R^5 are independently selected from hydrogen and methyl.

7. (Currently Amended) A compound according to claim 1 wherein Ar is selected from a group (a) or (b):



(a)



(b)

8. (Original) A compound of formula (Ia):



(Ia)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4.

9. (Previously Presented A compound according to claim 1 wherein m is 5 or 6 and n is 3 or 4.

10. (Previously Presented) A compound selected from the group consisting of:
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (Isomer 1);
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (Isomer 2);
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-{(1*R*)-2-[(6-{4-[4-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(Cyclohexylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(3-Cyclopenten-1-ylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({5-[3-(Cyclopentylsulfonyl)phenyl]pentyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[7-({3-[3-(Cyclopentylsulfonyl)phenyl]propyl}oxy)heptyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)-5-methylphenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
N-[5-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide;

4-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-fluorophenol;
6-{2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)pyridin-3-ol;
5-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-8-hydroxy-3,4-dihydroquinolin-2(1*H*)-one;
5-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-hydroxyphenylformamide;
salts thereof, solvates thereof, and physiologically functional derivatives thereof.

11. (Previously Presented) A compound according to Claim 10 which is:
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
or a salt, solvate, or physiologically functional derivative thereof.

12. (Previously Presented) A compound according to claim 1 in the form of a salt formed with an arylsulphonic acid.

13. (Previously Presented) A compound according to claim 8 which is selected from the group consisting of:
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol 4-methylbenzenesulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 4-bromobenzene sulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 4-chlorobenzene sulfonate
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 3-toluene sulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol 4-biphenyl sulfonate; and
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}

hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,naphthalene-2-sulfonate.

14. (Original) A compound according to claim 13 wherein the salt is in crystalline form.

15. (Currently Amended) A method for the ~~prophylaxis or~~ treatment of a clinical condition in a mammal, for which a selective β_2-adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, $-(CH_2)_gOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$,
$-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$,
and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, $-OR^{11}$ or $-NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{11}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $-OC(O)NR^{11}R^{12}$, R^{11} and R^{12} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4

~~according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof~~.

16. (Canceled)

17. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)



(b)



(c)

---

and



(d)

---

wherein R^8 represents hydrogen, halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$,
$-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$,
and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $–NHR^{14}$ and R^7 and $–NHR^{14}$ together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, $–OR^{11}$ or $–NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{11}$, $–NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $–OC(O)NR^{11}R^{12}$, R^{11} and R^{12} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl,
hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4

~~according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof~~, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

18. (Currently Amended) A combination comprising a compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, $-(CH_2)_gOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$,
$-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$,
and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, $-OR^{11}$ or $-NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{11}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $-OC(O)NR^{11}R^{12}$, R^{11} and R^{12} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4

~~according to claim 1~~ or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients.

19-21. (Canceled)

22. (Previously Presented) A compound according to claim 1, wherein R^{13} is a phenyl group.

23. (Previously Presented) A compound according to claim 1, wherein R^{13} is a naphthyl group.

24. (Previously Presented) A method according to Claim 15, wherein the mammal is a human.

25-34 (Canceled)

35. (New) A method according to Claim 15, wherein the clinical condition is asthma.

36. (New) A method according to Claim 15, wherein the clinical condition is COPD.